Navigation Links
Medarex Announces 2008 Fourth Quarter and Year End Financial Results
Date:2/25/2009

PRINCETON, N.J., Feb. 25 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today its financial results for the quarter and year ended December 31, 2008.

Medarex's net loss for the year ended December 31, 2008, was $38.5 million, or ($0.30) per share, as compared to a net loss of $27.1 million, or ($0.21) per share, for 2007. Medarex's net loss for 2008 includes a gain of $151.8 million, or $1.18 per share, from Medarex's sale of 2.5 million shares of Genmab A/S ("Genmab") stock in February 2008; a non-cash loss of $13.0 million, or ($0.10) per share, representing the loss associated with Medarex's ownership of Celldex Therapeutics, Inc. ("Celldex"); a non-cash charge of $22.1 million, or ($0.17) per share, for stock-based compensation recorded in accordance with FAS 123(R); and a non-cash impairment charge of $5.3 million, or ($0.04) per share, related to a write-down of Medarex's investment in three of its corporate partners. Excluding the impact of these items, Medarex's net loss on a non-GAAP basis for 2008 was $149.9 million, or ($1.17) per share.

Total revenues for the year ended December 31, 2008, decreased by $4.0 million from $56.3 million in 2007 to $52.3 million in 2008. Contract and license revenues increased by $0.4 million for the year ended December 31, 2008, from $35.9 million in 2007 to $36.3 million in 2008. Reimbursement of development costs for the year ended December 31, 2008, decreased by $4.4 million from $20.4 million in 2007 to $16.0 million in 2008 and relates primarily to the development of ipilimumab with Bristol-Myers Squibb Company.

Research and development (R&D) expenses for the year ended December 31, 2008, decreased by $3.4 million from $198.3 million in 2007 to $194.9 million in 2008. Included in R&D expense for the year ended December 31, 2008, is appro
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
2. Medarex to Present at the JPMorgan Small/Mid Cap Conference
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
5. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
7. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
8. Medarex Announces 2008 First Quarter Financial Results
9. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
10. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
11. Medarex Reviews Recent Highlights and Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... have identified the first genetic variant specifically associated ... accounting for around 10-15 per cent of all ... of the breast cancer sub-type, called invasive lobular ... causes of this particular kind of breast cancer, ... research, published today (Thursday) in the journal ...
(Date:4/17/2014)... to a study published today in PLOS Pathogens ... where malaria is common can mount an immune response ... to avoid repeated bouts of high fever and illness ... their bloodstream. The findings may help researchers develop future ... the malaria parasite. , Each year, approximately 200 million ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2
... A form of partial epilepsy associated with auditory and ... of brain development during early childhood, according to a ... Center (BIDMC). , Described in today,s Advance On-line issue ... the first genetic link between childhood brain development and ...
... can lessen stress when children get overwhelmed, experts say ... are nervous about the new school year can relax ... Experts at Duke University, in Durham, N.C., recommend mindfulness, ... children transition into the new school year and deal ...
... ... of Washington D.C. is business owner John Wahlquist of eMedicalSystems, Bremerton, Washington state. Author of ... unusual choice to retire his product and migrate his medical practices over to a new ... ...
... ... Reproduction Agency , ... (PRWEB) August 23, 2009 -- Steve Masler, CEO of The Donor Source International, LLC, a ... Donor Source of New England, that will focus on the New England Third-Party Reproduction market., ...
... , LOUISVILLE, Ky., Aug. 22 A top medical ... Legion and colleague veterans service organizations can play a key role ... national suicide prevention coordinator, in pointing to the 5,000 self-inflicted deaths ... of our responsibility to own up to that. There,s no reason ...
... poor prognosis in both blacks and whites after surgery, study ... the risk of prostate cancer recurrence in both black and ... suggesting obesity may be more significant for black men. , ... study senior author Dr. Stephen Freedland, an associate professor of ...
Cached Medicine News:Health News:Fragile period of childhood brain development could underlie epilepsy 2Health News:Soothe Back-to-School Anxiety, Teach Kids to Relax 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 3Health News:The American Legion Can Play Key Role in Vets' Suicide Prevention, Says VA 2Health News:Obesity Tied to Prostate Cancer Recurrence 2
(Date:1/15/2014)... 2014 The Cadence Fitness & Health Center has ... Medical Fitness Association, a non-profit organization assisting medically integrated ... The Cadence Fitness & Health Center is the only ... in the Chicagoland area. "The certification means ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 10, 2011 Life is unpredictable and can be even ... season, your runny nose, sneezing or itchy, watery eyes just ... Adventures contest on Facebook.  Allergy sufferers are invited to ... for a chance to win $5,000 toward a fun-filled adventure ...
... JACKSONVILLE, Fla., Aug. 10, 2011 MSC Care Management, ... care management solutions to the workers, compensation industry, introduces ... to help our customers manage patient care progress and ... to MSC customers, targets vital patient feedback on the ...
Cached Medicine Technology:Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures" 2Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures" 3Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures" 4MSC Monitors Patient Benchmarks on Behalf of Customers with MSC CareTrack 2
A quarter-vision dispensing case or table with a 6" high glass display area and halogen lights. Based on size of case, enjoy either 4, 5.5, 7 or 8 square feet respectively of elegant shelf space for ...
A compact showcase unit. Made with tempered glass, one, two or three adjustable shelves, a door with a safety lock. Equipped with fluorescent lighting and levelers. Display is available in various si...
Hoya Vision Care is focused on providing the best available most technically advanced and highest quality eye care products and services to the dispensing optometrist, ophthalmologist and optician....
... Essilor Laboratories of America ... trusted, spectacle lens lab network ... America. With in-house Crizal coating ... service and ensure premium quality ...
Medicine Products: